Cited by 139Advanced Drug Delivery SystemsNanoparticle-Based Drug DeliveryAdvancements in Transdermal Drug Delivery

The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.

Galantamine-loaded solid–lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations

Open access

Misra, Shubham, Chopra, Kanwaljit, Sinha, V. R., Medhi, Bikash·2016·Drug Delivery

DOI 10.3109/10717544.2015.1089956

Open this paper in CoChat — free account Open PDF

Abstract

Galantamine hydrobromide, a promising acetylcholinesterase inhibitor is reported to be associated with cholinergic side effects. Its poor brain penetration results in lower bioavailability to the target site. With an aim to overcome these limitations, solid-lipid nanoparticulate formulation of galantamine hydrobromide was developed employing biodegradable and biocompatible components. The selected galantamine hydrobromide-loaded solid-lipid nanoparticles offered nanocolloidal with size lower than 100 nm and maximum drug entrapment 83.42 ± 0.63%. In vitro drug release from these spherical drug-loaded nanoparticles was observed to be greater than 90% for a period of 24 h in controlled manner. In vivo evaluations demonstrated significant memory restoration capability in cognitive deficit rats in comparison with naive drug. The developed carriers offered approximately twice bioavailability to that of plain drug. Hence, the galantamine hydrobromide-loaded solid-lipid nanoparticles can be a promising vehicle for safe and effective delivery especially in disease like Alzheimer's.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3109/10717544.2015.1089956

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Place navigation impaired in rats with hippocampal lesions
Morris, R. G. M., Garrud, P., Rawlins, J. N. P., & O'Keefe, J. (1982) · Nature · doi:10.1038/297681a0 · Cited by 6,340
Untitled work
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
The Relationships Between Age, Sex, and the Incidence of Dementia and Alzheimer Disease
Gao, S., Hendrie, H. C., Hall, K. S., & Hui, S. L. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.9.809 · Cited by 782
Nanoparticle Surface Charges Alter Blood–Brain Barrier Integrity and Permeability
Lockman, P. R., Koziara, J. M., Mumper, R. J., & Allen, D. D. (2004) · Journal of drug targeting · doi:10.1080/10611860400015936 · Cited by 742
Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial
Wilcock, G. K., Lilienfeld, S., & Gaens, E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1445 · Cited by 623
Potential of solid lipid nanoparticles in brain targeting.
Kaur, I. P., Bhandari, R., Bhandari, S., & Kakkar, V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.018 · Cited by 615
Manufactured nanoparticles: their uptake and effects on fish—a mechanistic analysis
Handy, R. D., Henry, T. B., Scown, T. M., Johnston, B. D., & Tyler, C. R. (2008) · Ecotoxicology · doi:10.1007/s10646-008-0205-1 · Cited by 447
Effects of emulsifiers on the controlled release of paclitaxel (Taxol®) from nanospheres of biodegradable polymers
Feng, S., & Huang, G. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00364-3 · Cited by 400
Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease
Wilson, B., Samanta, M. K., Santhi, K., Kumar, K. P. S., Paramakrishnan, N., & Suresh, B. (2008) · Brain Research · doi:10.1016/j.brainres.2008.01.039 · Cited by 363
Allosteric Sensitization of Nicotinic Receptors by Galantamine, a New Treatment Strategy for Alzheimer’s Disease
Maelicke, A., Samochocki, M., Jostock, R., Fehrenbacher, A., Ludwig, J., Albuquerque, E. X., & Zerlin, M. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01109-4 · Cited by 303

Show all 40 references

Research works printed but not linked: 4

Muller RH, 1993, Proc Int Symp Control Rel Bioact Mater, 20, 480
Patel KB, 2010, J Chem Pharm Res, 2, 36
Shi F, 2012, Int J Nanomedicine, 7, 2033
Sruthi N, 2015, IJPCBS, 5, 63

Sorted by citations

Strategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
Alzheimer’s disease and its treatment by different approaches: A review
Srivastava, S., Ahmad, R., & Khare, S. K. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113320 · Cited by 506
Crossing the Blood–Brain Barrier: Recent Advances in Drug Delivery to the Brain
Patel, M. M., & Patel, B. M. (2017) · CNS Drugs · doi:10.1007/s40263-016-0405-9 · Cited by 430
Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061117 · Cited by 239
Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease
Karthivashan, G., Ganesan, P., Park, S., Kim, J.-S., & Choi, D. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1428243 · Cited by 229
Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges
Wen, M. M., El-Salamouni, N. S., El-Refaie, W. M., Hazzah, H. A., Ali, M. M., Tosi, G., Farid, R. M., Blanco‐Prieto, M. J., Billa, N., & Hanafy, A. S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.025 · Cited by 228
Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier
Lee, D., & Minko, T. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122049 · Cited by 227
Nano Carrier Drug Delivery Systems for the Treatment of Neuropsychiatric Disorders: Advantages and Limitations
Zorkina, Y., Abramova, O. V., Ushakova, V. M., Morozova, A. Y., Zubkov, E. A., Valikhov, M. P., Melnikov, P., Majouga, A. G., & Chekhonin, V. P. (2020) · Molecules · doi:10.3390/molecules25225294 · Cited by 166
ApoE-Targeting Increases the Transfer of Solid Lipid Nanoparticles with Donepezil Cargo across a Culture Model of the Blood–Brain Barrier
Topal, G. R., Mészáros, M., Porkoláb, G., Szecskó, A., Polgár, T. F., Siklós, L., Deli, M. A., Veszelka, S., & Bozkır, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010038 · Cited by 133
Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases
Teixeira, M. I., Lopes, C. M., Amaral, M. H., & Costa, P. C. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.01.005 · Cited by 133
Recent Advances in the Treatment of Alzheimer’s Disease Using Nanoparticle-Based Drug Delivery Systems
Poudel, P., & Park, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040835 · Cited by 124
Solid lipid nanoparticles for targeted natural and synthetic drugs delivery in high-incidence cancers, and other diseases: Roles of preparation methods, lipid composition, transitional stability, and release profiles in nanocarriers’ development
Mohammed, H. A., Khan, R. A., Singh, V., Yusuf, M., Akhtar, N., Sulaiman, G. M., Albukhaty, S., Abdellatif, A. A. H., Khan, M., Mohammed, S. A. A., et al. (2023) · Nanotechnology Reviews · doi:10.1515/ntrev-2022-0517 · Cited by 124
Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery
Maher, R., Moreno-Borrallo, A., Jindal, D., Mai, B. T., Ruiz‐Hernández, E., & Harkin, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030746 · Cited by 104
Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Hamano, N., Li, S., Chougule, M. B., Shoyele, S., Gupta, U. D., Ajazuddin, M., et al. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1471058 · Cited by 101
Improvement of memory deficits in the rat model of Alzheimer's disease by erythropoietin-loaded solid lipid nanoparticles
Dara, T., Vatanara, A., Sharifzadeh, M., Khani, S., Vakilinezhad, M. A., Vakhshiteh, F., Meybodi, M. N., Malvajerd, S. S., Hassani, S., & Mosaddegh, M. H. (2019) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2019.107082 · Cited by 92
Boosting the Brain Delivery of Atazanavir through Nanostructured Lipid Carrier-Based Approach for Mitigating NeuroAIDS
Khan, S. A., Rehman, S., Nabi, B., Iqubal, A., Nehal, N., Fahmy, U. A., Kotta, S., Baboota, S., Md, S., & Ali, J. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111059 · Cited by 89
Lipid-Based Nanocarriers for Neurological Disorders: A Review of the State-of-the-Art and Therapeutic Success to Date
Witika, B. A., Poka, M., Demana, P. H., Matafwali, S. K., Melamane, S., Khamanga, S. M., & Makoni, P. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040836 · Cited by 85
Nanoparticles in Combating Neuronal Dysregulated Signaling Pathways: Recent Approaches to the Nanoformulations of Phytochemicals and Synthetic Drugs Against Neurodegenerative Diseases
Fakhri, S., Abdian, S., Zarneshan, S. N., Moradi, S. Z., Farzaei, M. H., & Abdollahi, M. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s347187 · Cited by 83
Advances of nanosystems containing cyclodextrins and their applications in pharmaceuticals
Menezes, P. D. P., Andrade, T. D. A., Frank, L. A., de Souza, E. P. B. S. S., Trindade, G. G. G., Trindade, I. A. S., Serafini, M. R., Guterres, S. S., & Araújo, A. A. D. S. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.01.041 · Cited by 79
A comparison study of lipid and polymeric nanoparticles in the nasal delivery of meloxicam: Formulation, characterization, and in vitro evaluation
Akel, H., Ismail, R., Katona, G., Sabir, F., Ambrus, R., & Csóka, I. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120724 · Cited by 80
Nanotechnology to improve the Alzheimer’s disease therapy with natural compounds
Ramalho, M. J., Andrade, S., Loureiro, J. A., & do Carmo Pereira, M. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00694-3 · Cited by 75
Drug targeting strategies into the brain for treating neurological diseases
Barnabas, W. (2019) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2018.10.015 · Cited by 70
Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
Nunes, D., Loureiro, J. A., & Pereira, M. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112296 · Cited by 68
Expanding the Arsenal Against Huntington's Disease-Herbal Drugs and Their Nanoformulations
Vishwas, S., Gulati, M., Kapoor, B., Gupta, S., Singh, S. K., Awasthi, A., Khan, A., Goyal, A., Bansal, A. K., Baishnab, S., et al. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666201109090824 · Cited by 68
Neurotherapeutic applications of nanomedicine for treating Alzheimer's disease
Wilson, B., & Geetha, K. M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.044 · Cited by 67
Shortcut Approaches to Substance Delivery into the Brain Based on Intranasal Administration Using Nanodelivery Strategies for Insulin
Tashima, T. (2020) · Molecules · doi:10.3390/molecules25215188 · Cited by 61
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders
Неганова, М. Е., Aleksandrova, Y. R., Sukocheva, O. A., & Klochkov, S. G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.06.011 · Cited by 56
In vitro investigations on dopamine loaded Solid Lipid Nanoparticles
Cometa, S., Bonifacio, M. A., Trapani, G., Gioia, S. D., Dazzi, L., Giglio, E. D., & Trapani, A. (2020) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113257 · Cited by 54
Nasal delivery of neurotherapeutics via nanocarriers: Facets, aspects, and prospects
Rajput, A., Pingale, P., & Dhapte-Pawar, V. S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.979682 · Cited by 54
Inorganic Nanomaterials versus Polymer-Based Nanoparticles for Overcoming Neurodegeneration
Martano, S., Matteis, V. D., Cascione, M., & Rinaldi, R. (2022) · Nanomaterials · doi:10.3390/nano12142337 · Cited by 54
Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles
Islam, Y., Leach, A. G., Smith, J. A., Pluchino, S., Coxon, C. R., Sivakumaran, M., Downing, J. R., Fatokun, A. A., Teixidò, M., & Ehtezazi, T. (2021) · Advanced Science · doi:10.1002/advs.202002085 · Cited by 52
Alzheimer’s Disease and Parkinson’s Disease: A Review of Current Treatment Adopting a Nanotechnology Approach
Trompetero, A., Gordillo, A., del Pilar, M. C., Cristina, V., & Bustos, R. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666170828133059 · Cited by 49
Novel Therapeutic Strategies for Alzheimer’s Disease: Implications from Cell-Based Therapy and Nanotherapy
Derakhshankhah, H., Sajadimajd, S., Jafari, S., Izadi, Z., Sarvari, S., Sharifi, M., Falahati, M., Moakedi, F., Muganda, W. C. A., Müller, M., et al. (2020) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2020.102149 · Cited by 48
Biomaterials-based anti-inflammatory treatment strategies for Alzheimer’s disease
Chu, J., Zhang, W., Liu, Y., Gong, B., Ji, W., Yin, T., Gao, C., Liangwen, D., Hao, M., Chen, C., et al. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.374137 · Cited by 48
Advances in Nanomedicine for the Treatment of Alzheimer’s and Parkinson’s Diseases
Hernando, S., Gartziandia, O., Herrán, E., Pedraz, J. L., Igartúa, M., & Hernández, R. M. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0019 · Cited by 48
Neuroprotective effect of phytoconstituents via nanotechnology for treatment of Alzheimer diseases
Paramanick, D., Singh, V. D., & Singh, V. K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.058 · Cited by 47
Advancements in the Application of Nanomedicine in Alzheimer’s Disease: A Therapeutic Perspective
Puranik, N., Yadav, D., & Song, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814044 · Cited by 45
α-Bisabolol loaded solid lipid nanoparticles attenuates Aβ aggregation and protects Neuro-2a cells from Aβ induced neurotoxicity
Sathya, S., Shanmuganathan, B., Manirathinam, G., Kandasamy, R., & Devi, K. P. (2018) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2018.05.075 · Cited by 44
Brain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: A review
Jalili, C., Kiani, A., Gholami, M., Bahrehmand, F., Fakhri, S., Kakehbaraei, S., & Kakebaraei, S. (2023) · IET Nanobiotechnology · doi:10.1049/nbt2.12127 · Cited by 43
The Delivery Challenge in Neurodegenerative Disorders: The Nanoparticles Role in Alzheimer’s Disease Therapeutics and Diagnostics
de la Torre, C., & Ceña, V. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040190 · Cited by 42
Alzheimer’s Disease Targeted Nano-Based Drug Delivery Systems
Altinoglu, G., & Adalı, T. (2019) · Current Drug Targets · doi:10.2174/1389450120666191118123151 · Cited by 41
Plant-Derived Alkaloids
Dey, A., & Mukherjee, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809593-5.00006-9 · Cited by 40
Synthesis and evaluation of chitosan based controlled release nanoparticles for the delivery of ticagrelor
Shahid, N., Erum, A., Zaman, M., Tulain, U. R., Shoaib, Q.-U.-A., Malik, N. S., Kausar, R., Rashid, A., & Rehman, U. (2022) · Designed Monomers & Polymers · doi:10.1080/15685551.2022.2054117 · Cited by 38
The application of multifunctional nanomaterials in Alzheimer’s disease: A potential theranostics strategy
Xu, Y., Zhao, M.-N., Zhou, D., Zheng, T., & Zhang, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111360 · Cited by 38
Posterity of nanoscience as lipid nanosystems for Alzheimer's disease regression
Naser, S. S., Singh, D., Preetam, S., Kishore, S., Kumar, L., Nandi, A., Simnani, F. Z., Choudhury, A., Sinha, A., Mishra, Y. K., et al. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100701 · Cited by 37
Brain-targeted delivery of Valsartan using solid lipid nanoparticles labeled with Rhodamine B; a promising technique for mitigating the negative effects of stroke
Sabry, S. A., Razek, A. M. A. E., Nabil, M., Khedr, S. M., El-Nahas, H. M., & Eissa, N. G. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2179127 · Cited by 35
Nanomaterials that Aid in the Diagnosis and Treatment of Alzheimer's Disease, Resolving Blood–Brain Barrier Crossing Ability
Song, Q., Li, J., Li, T., & Li, H. (2024) · Advanced Science · doi:10.1002/advs.202403473 · Cited by 35
Nanotherapeutic strategies for the treatment of neurodegenerative diseases
Huang, M., Gu, X. Q., & Gao, X. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814001-7.00013-5 · Cited by 34
RETRACTED ARTICLE: Sialic acid-modified solid lipid nanoparticles as vascular endothelium-targeting carriers for ischemia-reperfusion-induced acute renal injury
Hu, J., Song, G.-L., Liu, D., Li, S., Wu, J., Kang, X.-Q., Qi, J., Jin, F., Wang, X., Xu, X., et al. (2017) · Drug Delivery · doi:10.1080/10717544.2017.1410258 · Cited by 32
Retracted
Targeting the central nervous system: From synthetic nanoparticles to extracellular vesicles—Focus on Alzheimer's and Parkinson's disease
Hernando, S., Santos‐Vizcaíno, E., Igartúa, M., & Hernández, R. M. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1898 · Cited by 32
Nanotechnology in the diagnostic and therapy for Alzheimer's disease
Panghal, A., & Flora, S. J. S. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130559 · Cited by 31
Antiviral Nanodelivery Systems: Current Trends in Acyclovir Administration
Hassan, H., Adam, S. K., Othman, F., Shamsuddin, A. F., & Basir, R. (2016) · Journal of Nanomaterials · doi:10.1155/2016/4591634 · Cited by 31
Preparation of Solid Lipid Nanoparticles of Cinnamaldehyde and Determination of Sustained Release Capacity
Chen, J., Li, S., Zheng, Q., Feng, X., Tan, W., Feng, K., Liu, Y., & Hu, W. (2022) · Nanomaterials · doi:10.3390/nano12244460 · Cited by 29
Tailoring lipid nanoconstructs for the oral delivery of paliperidone: Formulation, optimization and in vitro evaluation
Rehman, S., Nabi, B., Baboota, S., & Ali, J. (2020) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2020.105005 · Cited by 29
Pharmacological aspects of galantamine for the treatment of Alzheimer's disease
Kim, J. K., & Park, S. U. (2017) · EXCLI journal · doi:10.17179/excli2016-820 · Cited by 28
Parenteral microemulsions for drug delivery: Advances and update
Chavda, V. P., Gogoi, N. R., Vaghela, D. A., Balar, P. C., Dawre, S., & Dave, D. J. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104991 · Cited by 28
Nose-to-brain delivery of galantamine loaded nanospray dried polyacrylic acid/taurodeoxycholate mixed matrix as a protective therapy in lipopolysaccharide-induced Alzheimer’s in mice model
Elhabak, M., Salama, A. A. A., & Salama, A. H. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122588 · Cited by 27
Nano-integrated cascade antioxidases opsonized by albumin bypass the blood–brain barrier for treatment of ischemia-reperfusion injury
Wang, W., Zhang, Z., Liu, Y., Kong, L., Li, W., Hu, W., Wang, Y., & Liu, X. (2022) · Biomaterials Science · doi:10.1039/d2bm01401g · Cited by 26
Engineering of structural and functional properties of nanotherapeutics and nanodiagnostics for intranasal brain targeting in Alzheimer's
Hinge, N. S., Kathuria, H., & Pandey, M. M. (2021) · Applied Materials Today · doi:10.1016/j.apmt.2021.101303 · Cited by 25
Therapeutic nanotechnologies for Alzheimer’s disease: A critical analysis of recent trends and findings
Delbreil, P., Rabanel, J., Banquy, X., & Brambilla, D. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114397 · Cited by 25
Single and Multitarget Systems for Drug Delivery and Detection: Up-to-Date Strategies for Brain Disorders
Grosso, C., Silva, A., Delerue-Matos, C. M., & Barroso, M. F. (2023) · Pharmaceuticals · doi:10.3390/ph16121721 · Cited by 26
Nanobiotechnology in Neurodegenerative Diseases
Jampílek, J., Kráľová, K., Novák, P., & Novák, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_4 · Cited by 22
How nano-engineered delivery systems can help marketed and repurposed drugs in Alzheimer’s disease treatment?
Séguy, L., Groo, A., & Malzert‐Fréon, A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.02.022 · Cited by 23
Unraveling enhanced brain delivery of paliperidone-loaded lipid nanoconstructs: pharmacokinetic, behavioral, biochemical, and histological aspects
Rehman, S., Nabi, B., Javed, A., Khan, T. M., Iqubal, A., Ansari, M. J., Baboota, S., & Ali, J. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2069880 · Cited by 22
Low dimensional nanomaterials for treating acute kidney injury
Nie, Y., Wang, L., You, X., Wang, X., Wu, J., & Zheng, Z. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01712-2 · Cited by 22
Therapeutic considerations of bioactive compounds in Alzheimer's disease and Parkinson's disease: Dissecting the molecular pathways
Phukan, B. C., Roy, R., Gahatraj, I., Bhattacharya, P., & Borah, A. (2023) · Phytotherapy Research · doi:10.1002/ptr.8012 · Cited by 22
Nanoparticles: a new frontier in neurodegenerative disease therapy
Kumar, V., Sharma, S., & Singh, A. K. (2025) · Frontiers in Medical Technology · doi:10.3389/fmedt.2025.1654003 · Cited by 22
Biomaterials Comprising Implantable and Dermal Drug Delivery Targeting Brain in Management of Alzheimer’s Disease: A Review
Kiran, N. S., Vaishnavi, G., Singh, S. K., Yashaswini, C., Parihar, A., Pal, S., Kaur, J., Prajapati, B. G., Mohite, P. B., & Puri, A. V. (2024) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-024-00340-6 · Cited by 20
“Plurol will not miss the boat”: A new manifesto of galantamine conveyance
Gad, H. A., Mansour, M., Abbas, H., Malatani, R. T., Khattab, M. A., & Elmowafy, E. M. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103516 · Cited by 18
Nanotechnology‐empowered therapeutics targeting neurodegenerative diseases
Wang, Z., Gonzalez, K. M., Cordova, L. E., & Lu, J. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1907 · Cited by 18
Targeted drug delivery: designing nanocarriers for improved therapeutic action
Hussain, S., Arif, A., Mujeeb-ur-Rehman, & Shah, M. R. (2026) · Chemical Communications · doi:10.1039/d5cc07306e · Cited by 18
Recent Nanoscale Carriers for Therapy of Alzheimer's Disease: Current Strategies and Perspectives
Zakharova, L. Y., Gaynanova, G. A., Vasilieva, E. A., Vasileva, L. A., Pavlov, R. V., Kashapov, R. R., Petrov, K. A., & Sinyashin, O. G. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867330666221115103513 · Cited by 16
Nanotherapeutics for Alzheimer's Disease with Preclinical Evaluation and Clinical Trials: Challenges, Promises and Limitations
Bukhari, S. N. A. (2021) · Current Drug Delivery · doi:10.2174/1567201818666210910162750 · Cited by 16
Comparative evaluation of fish oil and butter oil in modulating delivery of galantamine hydrobromide to brain via intranasal route: pharmacokinetic and oxidative stress studies
Katdare, A., Khunt, D., Thakkar, S., Polaka, S., & Misra, M. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00739-y · Cited by 15
Particulate systems for improving therapeutic efficacy of pharmaceuticals against central nervous system-related diseases
Kuo, Y., & Rajesh, R. (2020) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2020.09.012 · Cited by 15
LC-MS bioanalysis of targeted nasal galantamine bound chitosan nanoparticles in rats’ brain homogenate and plasma
Agami, M. A., Shaalan, R. A., Belal, S., & Ragab, M. A. A. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03487-1 · Cited by 14
Drug Target to Alleviate Mitochondrial Dysfunctions in Alzheimer’s Disease: Recent Advances and Therapeutic Implications
Rahman, M. A., Rahman, M. H., Rhim, H., & Kim, B. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666240426091311 · Cited by 14
Exosomes and non-coding RNAs: bridging the gap in Alzheimer’s pathogenesis and therapeutics
Chunhui, G., You, Y., Chen, J., Luo, N., & Li, F. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-024-01520-7 · Cited by 13
Nanomedicine-Driven Therapeutic Interventions of Autophagy and Stem Cells in The Management of Alzheimer’s Disease
Alhodieb, F. S., Rahman, M. A., Barkat, M. A., Alanezi, A. A., Barkat, H. A., Hadi, H. A., Harwansh, R. K., & Mittal, V. (2023) · Nanomedicine · doi:10.2217/nnm-2022-0108 · Cited by 13
Antioxidants Against Neurological Disorders
Narang, J. K., Dogra, A., Kaur, T., Narang, R. S., & Singh, A. P. (2024) · Antioxidants · doi:10.1002/9781394270576.ch9 · Cited by 12
Galactomannan-Decorated Lipidic Nanocarrier for Gene Supplementation Therapy in Fabry Disease
Rodríguez-Castejón, J., Gómez-Aguado, I., Beraza-Millor, M., Solinís, M. Á., del Pozo‐Rodríguez, A., & Rodríguez‐Gascón, A. (2022) · Nanomaterials · doi:10.3390/nano12142339 · Cited by 11
Vibrational spectroscopic study of selected alkaloids with therapeutic effects
Švecová, M., Palounek, D., Volochanskyi, O., & Prokopec, V. (2019) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2019.117969 · Cited by 11
Nanotechnology in Oral Drug Delivery: Salient Aspects, State of Art, and Applications
Patel, M., Joshi, G., & Sawant, K. K. (2020) · Nanotechnology in the life sciences · doi:10.1007/978-3-030-41464-1_8 · Cited by 10
Development of Brain Permeable Drugs and Novel Strategies to Overcome the Brain Barriers for Treatment Purposes
Chauhan, A., & Jain, S. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128386983250410092649 · Cited by 10
Thermoresponsive poly(N-isopropylacrylamide) copolymer networks for galantamine hydrobromide delivery
Georgieva, D., Ivanova‐Mileva, K., Ivanova, S., Kostova, B., Rachev, D., & Christova, D. (2020) · Colloid & Polymer Science · doi:10.1007/s00396-020-04621-8 · Cited by 9
A comparative in vivo Evaluation of Anti-Alzheimer Activity of Bacopa Extract and its Solid Lipid Nanoparticles
Kumar, R., Garg, R., & Khurana, N. (2020) · Current Bioactive Compounds · doi:10.2174/1573407216999201113121756 · Cited by 8
Nanoparticle delivery for central nervous system diseases and its clinical application
Tang, L., Zhang, R., Wang, Y., Liu, M., Hu, D., Wang, Y., & Li, Y. (2024) · Nano Research · doi:10.1007/s12274-024-6598-1 · Cited by 8
Tau-aggregation inhibition: promising role of nanoencapsulated dietary molecules in the management of Alzheimer’s disease
Nagaraju, P. G., Ashwini, S., & G., P. P. C. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2092446 · Cited by 7
SOLID LIPID NANOPARTILCES: MODERN PROGRESS IN NOSE-TO-BRAIN TRANSDUCTION
SOWMYA, C., Kannan, S. P., & H., A. A. (2023) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2023v15i4.47897 · Cited by 7
Nanotechnology Based Delivery Systems of Drugs Currently Used to Treat Alzheimer’s Disease
Choubdar, N., & Avizheh, S. (2019) · Nanoscience & Nanotechnology-Asia · doi:10.2174/2210681209666190228143636 · Cited by 7
Lipid-based nanostructures in targeted management of neurological disorders: A comprehensive review
Guleria, M., Kamble, A., Upadhyay, M., Sethi, P., Patel, M. B., Malhan, A., Rastogi, S., Datta, D., Singh, S. A., & Prajapati, B. G. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126530 · Cited by 6
Nanotherapeutic smart approaches for combating Alzheimer’s disease and overcoming existing obstacles: A novel eco-friendly green approach
Almehdi, A. M., Baker, D. H. A., Hamdy, R., & El‐Keblawy, A. A. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101906 · Cited by 6
Recent Trends in Nano-Particulate Carriers for the Diagnosis and Treatment of Alzheimer’s Disease
Yadav, A. K., & Mazahir, F. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220420133059 · Cited by 6
Extravaganza of Nanobiotechnology in the Diagnosis and Treatment of Dementia Patients
Bhattacharya, S. (2022) · Current Pharmaceutical Biotechnology · doi:10.2174/1385272827666221027103050 · Cited by 6
Breaking Barriers in Alzheimer’s Disease: the Role of Advanced Drug Delivery Systems
Shekho, D., Mishra, R., Kamal, R., Bhatia, R., & Awasthi, A. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02923-6 · Cited by 6
Acetylcholinesterase inhibitors and nanoparticles on Alzheimer’s disease: a review
Silva, S., Almeida, A. J., & Vale, N. (2021) · Journal of Nanoparticle Research · doi:10.1007/s11051-020-05118-9 · Cited by 6
Nanoparticles as an Encouraging Therapeutic Approach to Alzheimer’s Disease
Batko, J., Antosz, K., Nowakowska, H., Błażejewska, M., Kowalik, E. M., Beszłej, J. A., & Leszek, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167725 · Cited by 5
Comprehending Alzheimer's Disease: Molecular Mechanisms and Treatment Strategies
Rathee, S., Pandey, V., Soni, S., Sen, D., & Jain, S. (2025) · Current Alzheimer Research · doi:10.2174/0115672050368798250626075628 · Cited by 6
Nanoparticle-mediated delivery of AChE inhibitors for the treatment of Alzheimer’s disease
Namdeo, P., Mathew, J., & Garg, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85544-0.00004-6 · Cited by 5

Authors: Misra, S., Chopra, K., Sinha, V. R., & Medhi, B.
Affiliations: Post Graduate Institute of Medical Education and Research (IN)
Panjab University (IN)
Corresponding author: Medhi, Bikash
ORCID: Misra, Shubham
Chopra, Kanwaljit
Sinha, V. R.
Medhi, Bikash
Venue: Drug Delivery
Publisher: Informa UK Limited
Published: 2015-09-25
Volume: 23
Issue: 4
Pages: 1434-1443
ISSN: 1071-7544 (ISSN-L)
1521-0464
DOI: 10.3109/10717544.2015.1089956
OpenAlex: W1867774233
Cited by: 136
References: 40
Citations by year: 2026: 12 · 2025: 14 · 2024: 11 · 2023: 19 · 2022: 29 · 2021: 10 · 2020: 16 · 2019: 9 · 2018: 7 · 2017: 6 · 2016: 3
FWCI: 2.96
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Drug Delivery (publishedVersion)
PubMed (publishedVersion)
Funders: Sun Pharma
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
Keywords: galantamine hydrobromide, solid lipid nanoparticles, brain drug delivery, acetylcholinesterase inhibitors, Alzheimer's disease, encapsulation efficiency, controlled drug release, cognitive impairment, bioavailability enhancement, nanocarriers
MeSH terms: Animals, Brain, Cholinesterase Inhibitors, Drug Carriers, Galantamine, Lipids, Drug Delivery Systems, Rats, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Galantamine-loaded solid–lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks